Segment Information (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Schedule of Information for the Company's Operating Segments

Information for the Company's reportable segments for the three months ended September 30, 2017 and 2016 are as follows:

Three Months Ended September 30, 2017	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	413,601	—	—	$	413,601
Interest income, net	$	—	—	77,339	$	77,339
Loss from operations	$	2,323,919	4,683,533	2,402,000	$	9,409,452

Three Months Ended September 30, 2016	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	599,074	—	—	$	599,074
Interest income, net	$	—	—	97,726	$	97,726
Loss from operations	$	2,690,601	5,550,853	2,493,766	$	10,735,220

Information for the Company's reportable segments for the nine months ended September 30, 2017 and 2016 are as follows:

Nine Months Ended September 30, 2017	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	991,671	—	—	$	991,671
Interest income, net	$	—	—	227,535	$	227,535
Loss from operations	$	7,072,225	12,472,149	7,088,292	$	26,632,666

Nine Months Ended September 30, 2016	Consumer Operations		Drug Development	Corporate	Consolidated
Total revenue	$	711,759	—	—	$	711,759
Interest income, net	$	—	—	308,877	$	308,877
Loss from operations	$	8,461,803	15,517,670	7,922,492	$	31,901,965